Skip to main
ARDX
ARDX logo

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx Inc demonstrated a strong financial performance with total revenue exceeding consensus estimates by approximately $16 million, driven by an $8 million contribution from its IBS treatment, Ibsrela. The company highlighted a healthy 27% quarter-over-quarter growth when excluding one-time benefits, reaffirming peak U.S. revenue guidance of $750 million prior to patent expiration. Additionally, Xphozah's U.S. net sales surpassed consensus by around $3 million, indicating successful initial implementation of strategies to address changes in Medicare Part D coverage.

Bears say

Ardelyx Inc faces significant challenges in the near term due to the recent loss of Medicare Part D coverage for its Xphozah product, which could adversely affect its market penetration among a crucial demographic. The company has demonstrated some ability to adjust its strategy by targeting the non-Medicare patient population, but the absence of financial guidance for FY25 raises concerns about future revenue stability and growth prospects. This uncertainty may hinder investor confidence and negatively impact the stock's performance moving forward.

Ardelyx (ARDX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Buy based on their latest research and market trends.

According to 9 analysts, Ardelyx (ARDX) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.